Original language | English (US) |
---|---|
Pages (from-to) | 2450-2452 |
Number of pages | 3 |
Journal | Journal of Allergy and Clinical Immunology: In Practice |
Volume | 8 |
Issue number | 7 |
DOIs | |
State | Published - Jul 1 2020 |
ASJC Scopus subject areas
- Immunology and Allergy
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Journal of Allergy and Clinical Immunology: In Practice, Vol. 8, No. 7, 01.07.2020, p. 2450-2452.
Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Reply to “Subcutaneous terbutaline as an alternative to aerosolized albuterol”
AU - Shaker, Marcus S.
AU - Oppenheimer, John
AU - Grayson, Mitchell
AU - Stukus, David
AU - Hartog, Nicholas
AU - Hsieh, Elena W.Y.
AU - Rider, Nicholas
AU - Dutmer, Cullen M.
AU - Vander Leek, Timothy K.
AU - Kim, Harold
AU - Chan, Edmond S.
AU - Mack, Doug
AU - Ellis, Anne K.
AU - Lang, David
AU - Lieberman, Jay
AU - Fleischer, David
AU - Golden, David B.K.
AU - Wallace, Dana
AU - Portnoy, Jay
AU - Mosnaim, Giselle
AU - Greenhawt, Matthew
N1 - Funding Information: Conflicts of interest: M. S. Shaker is a member of the Joint Taskforce on Allergy Practice Parameters; has a family member who is CEO of Altrix Medical; and serves on the Editorial Board of the Journal of Food Allergy and the Annals of Allergy, Asthma, and Immunology. J. Oppenheimer has received research/adjudication support from AstraZeneca (AZ), GlaxoSmithKline (GSK), Sanofi, and Novartis; is a consultant for GSK, AZ, and Sanofi; is Associate Editor of Annals of Allergy Asthma Immunology and AllergyWatch; is Section Editor for Current Opinion of Allergy; receives royalties from UpToDate; is Board Liaison ABIM for ABAI; and is a member of the Joint Taskforce on Allergy Practice Parameters. M. Grayson is a medical advisory board participant for Aimmune, DBV, and Genzyme; is Director and Treasurer of the ABAI; is Associate Editor of the Annals of Allergy, Asthma, and Immunology; is Chair of the Medical Scientific Council of the Asthma and Allergy Foundation of America; and is a member of the Scientific Advisory Committee of the American Lung Association. D. Stukus is a consultant for DBVTherapeutics, Before Brands, and Abbott Nutrition. N. Hartog is a speaker for and on the advisory board for Horizon Pharmaceuticals; is a speaker for Takeda; and is on the advisory board for Orchard Therapeutics. E. W. Y. Hsieh is supported by NIH NIAMS K23AR070897, the Boettcher Foundation Webb-Waring Biomedical research grant, the CARRA large grant, the Jeffrey Modell Foundation Translational Award, and Takeda Pharmaceuticals. N. Rider is a consultant and on the Scientific Advisory Boards for Horizon Therapeutics, CSL Behring, and Takeda Pharmaceuticals; receives royalties from Kluwer Wolters; is an UpToDate Topic Contributor; and receives grant funding from the Jeffrey Model Foundation. C. M. Dutmer has no relevant conflicts of interest. T. K. Vander Leek has served on advisory boards for Aralez and Pediapharm; has served on speaker bureaus for and received honoraria from Aralez, Pediapharm and Pfizer; and currently serves as Vice President for the CSACI. H. Kim has served on speakers' bureau and Advisory Boards for AstraZeneca, Aralez, Boehringer Ingelheim, CSL Behring, Kaleo, Merck, Mylan, Novartis, Pediapharm, Sanofi, Shire, and Teva; and has received research funding from AstraZeneca, Shire, Sanofi, and Novartis. E. S. Chan has received research support from DBV Technologies; has been a member of advisory boards for Pfizer, Pediapharm, Leo Pharma, and Kaleo; is a member of the scientific advisory board for Food Allergy Canada; and was an expert panel and coordinating committee member of the National Institute of Allergy and Infectious Diseases (NIAID)-sponsored Guidelines for Peanut Allergy Prevention. D. Mack is a member of the Board of Directors for the Canadian Society of Allergy and Clinical Immunology; serves on the Editorial Board of the Journal of Food Allergy; has provided consultation and speaker services for Pfizer, Aimmune, Merck, Covis, and Pediapharm; and has been part of an advisory board for Pfizer and Bausch Health. A. K. Ellis has received financial support from ALK Abello, AstraZeneca, Green Cross, Merck, Novartis, Nuvo, Pediapharm, Pfizer, Kaleo, Novartis, Sanofi, and Regeneron; and serves on the Board of Directors of the Canadian Allergy Society of Allergy and Clinical Immunology. D. Lang is on the Editorial Board for Allergy and Asthma Proceedings; is Topic Editor for DynaMed; is Associate Editor for J Asthma; and is Delegate to NQF representing the American Academy of Allergy, Asthma, and Immunology (AAAAI). J. Lieberman has received research support (money to institution) from DBV, Aimmune, and Regeneron; is on the Advisory Boards for DBV, Genentech, and Covis; and is a Consultant for Kaleo. D. Fleischer received institutional research funding from DBV Technologies; institutional research funding from Aimmune Therapeutics; has served as a consultant and received personal fees from DBV Technologies, Aimmune Therapeutics, Kaleo Pharmaceutical, INSYS Therapeutics, Abbott, Allergenis, Acquestive, and Nestle; is a non-paid member of the scientific advisory council for the National Peanut Board and a non-paid member of clinical advisory boards for Food Allergy Research & Education and Food Allergy and Anaphylaxis Connectivity Team. D. B. K. Golden has received financial support from Aquestive, Sandoz, ALK-Abello, Genentech, Stallergenes-Greer, and UpToDate. D. Wallace has received financial support from Mylan, Kaleo, Optinose, ALK, Bryan, and Sanofi. J. Portnoy has received financial support from Thermofisher, Kaleo, Teva, Novartis, Hycor, and Boehringer-Ingelheim. G. Mosnaim received research grant support from AstraZeneca and GlaxoSmithKline; currently receives research grant support from Propeller Health; owned stock in Electrocore; and served as a consultant and/or member of a scientific advisory board for GlaxoSmithKline, Sanofi-Regeneron, Teva, Novartis, Astra Zeneca, Boehringer Ingelheim, and Propeller Health. M. Greenhawt is supported by grant #5K08HS024599-02 from the Agency for Healthcare Research and Quality; is an expert panel and coordinating committee member of the NIAID-sponsored Guidelines for Peanut Allergy Prevention; has served as a consultant for the Canadian Transportation Agency, Thermo Fisher, Intrommune, and Aimmune Therapeutics; is a member of physician/medical advisory boards for Aimmune Therapeutics, DBV Technologies, Sanofi/Genzyme, Genentech, Nutricia, Kaleo Pharmaceutical, Nestle, Acquestive, Allergy Therapeutics, Allergenis, Aravax, and Monsanto; is a member of the scientific advisory council for the National Peanut Board; has received honorarium for lectures from Thermo Fisher, Aimmune Therapeutics, DBV Technologies, Before Brands, multiple state allergy societies, the American College of Allergy Asthma and Immunology, the European Academy of Allergy and Clinical Immunology; is Associate Editor for the Annals of Allergy, Asthma, and Immunology; and is a member of the Joint Taskforce on Allergy Practice Parameters. Funding Information: Conflicts of interest: M. S. Shaker is a member of the Joint Taskforce on Allergy Practice Parameters; has a family member who is CEO of Altrix Medical; and serves on the Editorial Board of the Journal of Food Allergy and the Annals of Allergy, Asthma, and Immunology. J. Oppenheimer has received research/adjudication support from AstraZeneca (AZ), GlaxoSmithKline (GSK), Sanofi , and Novartis ; is a consultant for GSK, AZ, and Sanofi; is Associate Editor of Annals of Allergy Asthma Immunology and AllergyWatch; is Section Editor for Current Opinion of Allergy; receives royalties from UpToDate; is Board Liaison ABIM for ABAI; and is a member of the Joint Taskforce on Allergy Practice Parameters. M. Grayson is a medical advisory board participant for Aimmune, DBV, and Genzyme; is Director and Treasurer of the ABAI; is Associate Editor of the Annals of Allergy, Asthma, and Immunology; is Chair of the Medical Scientific Council of the Asthma and Allergy Foundation of America; and is a member of the Scientific Advisory Committee of the American Lung Association. D. Stukus is a consultant for DBVTherapeutics, Before Brands, and Abbott Nutrition. N. Hartog is a speaker for and on the advisory board for Horizon Pharmaceuticals; is a speaker for Takeda; and is on the advisory board for Orchard Therapeutics. E. W. Y. Hsieh is supported by NIH NIAMS K23AR070897, the Boettcher Foundation Webb-Waring Biomedical research grant, the CARRA large grant, the Jeffrey Modell Foundation Translational Award, and Takeda Pharmaceuticals . N. Rider is a consultant and on the Scientific Advisory Boards for Horizon Therapeutics, CSL Behring, and Takeda Pharmaceuticals; receives royalties from Kluwer Wolters; is an UpToDate Topic Contributor; and receives grant funding from the Jeffrey Model Foundation . C. M. Dutmer has no relevant conflicts of interest. T. K. Vander Leek has served on advisory boards for Aralez and Pediapharm; has served on speaker bureaus for and received honoraria from Aralez, Pediapharm and Pfizer; and currently serves as Vice President for the CSACI. H. Kim has served on speakers' bureau and Advisory Boards for AstraZeneca, Aralez, Boehringer Ingelheim, CSL Behring, Kaleo, Merck, Mylan, Novartis, Pediapharm, Sanofi, Shire, and Teva; and has received research funding from AstraZeneca , Shire , Sanofi , and Novartis . E. S. Chan has received research support from DBV Technologies ; has been a member of advisory boards for Pfizer, Pediapharm, Leo Pharma, and Kaleo; is a member of the scientific advisory board for Food Allergy Canada; and was an expert panel and coordinating committee member of the National Institute of Allergy and Infectious Diseases (NIAID)-sponsored Guidelines for Peanut Allergy Prevention . D. Mack is a member of the Board of Directors for the Canadian Society of Allergy and Clinical Immunology; serves on the Editorial Board of the Journal of Food Allergy; has provided consultation and speaker services for Pfizer, Aimmune, Merck, Covis, and Pediapharm; and has been part of an advisory board for Pfizer and Bausch Health. A. K. Ellis has received financial support from ALK Abello , AstraZeneca , Green Cross , Merck , Novartis , Nuvo , Pediapharm , Pfizer , Kaleo , Novartis , Sanofi , and Regeneron ; and serves on the Board of Directors of the Canadian Allergy Society of Allergy and Clinical Immunology. D. Lang is on the Editorial Board for Allergy and Asthma Proceedings; is Topic Editor for DynaMed; is Associate Editor for J Asthma; and is Delegate to NQF representing the American Academy of Allergy, Asthma, and Immunology (AAAAI). J. Lieberman has received research support (money to institution) from DBV , Aimmune , and Regeneron; is on the Advisory Boards for DBV, Genentech, and Covis; and is a Consultant for Kaleo. D. Fleischer received institutional research funding from DBV Technologies ; institutional research funding from Aimmune Therapeutics ; has served as a consultant and received personal fees from DBV Technologies, Aimmune Therapeutics, Kaleo Pharmaceutical, INSYS Therapeutics, Abbott, Allergenis, Acquestive, and Nestle; is a non-paid member of the scientific advisory council for the National Peanut Board and a non-paid member of clinical advisory boards for Food Allergy Research & Education and Food Allergy and Anaphylaxis Connectivity Team. D. B. K. Golden has received financial support from Aquestive , Sandoz , ALK-Abello , Genentech , Stallergenes-Greer , and UpToDate. D. Wallace has received financial support from Mylan , Kaleo , Optinose , ALK , Bryan , and Sanofi . J. Portnoy has received financial support from Thermofisher , Kaleo , Teva , Novartis , Hycor , and Boehringer-Ingelheim . G. Mosnaim received research grant support from AstraZeneca and GlaxoSmithKline ; currently receives research grant support from Propeller Health ; owned stock in Electrocore; and served as a consultant and/or member of a scientific advisory board for GlaxoSmithKline, Sanofi-Regeneron, Teva, Novartis, Astra Zeneca, Boehringer Ingelheim, and Propeller Health. M. Greenhawt is supported by grant #5K08HS024599-02 from the Agency for Healthcare Research and Quality ; is an expert panel and coordinating committee member of the NIAID-sponsored Guidelines for Peanut Allergy Prevention; has served as a consultant for the Canadian Transportation Agency, Thermo Fisher, Intrommune, and Aimmune Therapeutics; is a member of physician/medical advisory boards for Aimmune Therapeutics, DBV Technologies, Sanofi/Genzyme, Genentech, Nutricia, Kaleo Pharmaceutical, Nestle, Acquestive, Allergy Therapeutics, Allergenis, Aravax, and Monsanto; is a member of the scientific advisory council for the National Peanut Board; has received honorarium for lectures from Thermo Fisher, Aimmune Therapeutics, DBV Technologies, Before Brands, multiple state allergy societies, the American College of Allergy Asthma and Immunology, the European Academy of Allergy and Clinical Immunology; is Associate Editor for the Annals of Allergy, Asthma, and Immunology; and is a member of the Joint Taskforce on Allergy Practice Parameters.
PY - 2020/7/1
Y1 - 2020/7/1
UR - http://www.scopus.com/inward/record.url?scp=85083771834&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85083771834&partnerID=8YFLogxK
U2 - 10.1016/j.jaip.2020.04.016
DO - 10.1016/j.jaip.2020.04.016
M3 - Letter
C2 - 32340824
AN - SCOPUS:85083771834
SN - 2213-2198
VL - 8
SP - 2450
EP - 2452
JO - Journal of Allergy and Clinical Immunology: In Practice
JF - Journal of Allergy and Clinical Immunology: In Practice
IS - 7
ER -